Feasibility Study of the Vedera KXS for Treatment of Keratoconus

Keratoconus Clinical Trial

Official title:

Feasibility Study of the Vedera KXS for Treatment of Keratoconus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01069848
• Other study ID #: Avedro T4
• Status: Completed
• Phase: N/A
• Start date: January 2010
• Est. completion date: March 2011

Study information

• Verified date: April 2021
• Source: Glaukos Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this investigation is to evaluate the feasibility, safety and efficacy of the Vedera KXS for the reduction or elimination of myopia and astigmatism in patients with keratoconus, who are no longer able to achieve adequate vision with their contact lenses or glasses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: March 2011
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 100 Years

Eligibility

Inclusion Criteria:

1. 14 years of age or older

2. Presence of central or inferior steepening on the Pentacam map

3. Axial topography consistent with keratoconus

4. I-S ratio > 1.5 on the Pentacam map or topography map

5. BSCVA worse than 20/20 (<53 letters on ETDRS chart)

6. Contact Lens Wearers Only: Removal of contact lenses for the required period of time prior to the screening refraction

7. Signed written informed consent

8. Willingness and ability to comply with schedule for follow-up visits

Exclusion Criteria:

1. Eyes classified as either normal or atypical normal on the keratoconus severity grading scheme.

2. A history of previous corneal surgery or the insertion of Intacs in the eye(s) to be treated.

3. Corneal pachymetry <400 microns at diameter to be treated.

4. Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example:

1. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.)

2. Clinically significant corneal scarring in the treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the treatment.

5. A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.

6. Diagnosed with autoimmune disease, systemic connective tissue diseases or atopic syndrome, diabetes mellitus, or taking systemic medications likely to affect wound healing.

7. Women who are pregnant or nursing or who plan to become pregnant over the course of their participation in this investigation.

Related Conditions & MeSH terms

• Keratoconus

Intervention

Device:
• Vedera KXS
One treatment session with Vedera KXS

Locations

Country	Name	City	State
Turkey	Beyoglu Eye Hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Glaukos Corporation

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The reduction in Kmax (by keratometry) of >1 D		3 months